Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Atterocor changes name to Millendo, gets $62mm in Series B

Executive Summary

Atterocor changed its name to Millendo Therapeutics Inc. to reflect its focus on endocrine therapies, and raised $62mm in Series B financing. New Enterprise Associates led and was joined by other new backers Roche Venture Fund, Adams Street Partners, Altitude Life Science Ventures, Longwood Fund, and Renaissance Venture Capital Fund, and returning shareholders Frazier Healthcare Partners, Osage University Partners, 5AM Ventures, and the Regents of the University of Michigan. A representative from Roche Venture Fund and NEA will join Millendo’s board. Concurrent with the round, Millendo acquired exclusive rights to AstraZeneca's Phase II AZD4901 (renamed MLE4901) for polycystic ovary syndrome.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies